VANCOUVER, BC & OTTAWA, ON – Qu Biologics Inc., a company that has developed a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, is partnering with a University of Ottawa assistant professor Dr. Adam Shuhendler, to address advanced questions regarding trafficking of administered biologics.
By nature, biologics, which include therapies such as vaccines and antibodies, as well as Qu Biologics’ Site Specific Immunomodulators (SSIs), are difficult to properly track in living organisms. Therefore, their ultimate fate and metabolism remains largely unknown. The Natural Sciences and Engineering Research Council (NSERC) of Canada awarded an Engage grant to enable Qu Biologics and Dr. Shuhendler to tackle this important question together.
Engage grants are designed to provide innovative Canadian companies access to special expertise and capabilities available at Canadian universities.
“We anticipate this work will lead to a detailed understanding of the fate of SSIs in living systems, and equally importantly, it will provide us with new tools to study biologics,” Dr. Shirin Kalyan, Qu Biologics’ director of scientific innovation, said.
Dr. Kalyan and Dr. Mark Bazett, Qu Biologics’ preclinical lead, will work with Dr. Shuhendler’s group on this novel approach to trace biologics in vivo.